Biohaven Pharmaceutical Holding Co is a biotechnology business based in the US. Biohaven Pharmaceutical Holding Co shares (BHVN) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $46.83 – a decrease of 3.76% over the previous week. Biohaven Pharmaceutical Holding Co employs 239 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $46.83 |
|---|---|
| 52-week range | $26.80 - $62.21 |
| 50-day moving average | $47.77 |
| 200-day moving average | $43.74 |
| Wall St. target price | $65.14 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-9.37 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $46.3 from 2024-11-19
| 1 week (2024-11-14) | -4.85% |
|---|---|
| 1 month (2024-10-21) | -9.82% |
| 3 months (2024-08-21) | 12.13% |
| 6 months (2024-05-21) | 19.58% |
| 1 year (2023-11-21) | 56.79% |
|---|---|
| 2 years (2022-11-21) | 222.87% |
| 3 years (2021-11-18) | N/A |
| 5 years (2019-11-18) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -118.79% |
| Return on equity TTM | -265.45% |
| Profit margin | 0% |
| Book value | $3.33 |
| Market Capitalization | $4.9 billion |
TTM: trailing 12 months
We're not expecting Biohaven Pharmaceutical Holding Co to pay a dividend over the next 12 months.
Over the last 12 months, Biohaven Pharmaceutical Holding Co's shares have ranged in value from as little as $26.8 up to $62.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Biohaven Pharmaceutical Holding Co's is 4.12. This would suggest that Biohaven Pharmaceutical Holding Co's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Biohaven Ltd. , together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc. , Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.